ProCE Banner Activity

Islatravir Once Monthly for PrEP Demonstrates Favorable Safety/Tolerability and Meets Pharmacokinetic Threshold Target in Blinded Interim Analysis of Phase IIa Trial

Slideset Download
Conference Coverage
Interim analysis showed that islatravir administered once monthly achieved the prespecified pharmacokinetic threshold for predicted HIV pre-exposure prophylaxis efficacy.

Released: January 30, 2021

Expiration: January 29, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2021 HIV R4P

ProCE Banner